KalVista Pharmaceuticals (KALV) Share-based Compensation (2014 - 2025)

KalVista Pharmaceuticals has disclosed Share-based Compensation across 12 years of filings, most recently posting $5.4 million for Q3 2025.

• Share-based Compensation for Q3 2025 came in at $5.4 million, up 76.94% year-over-year; the trailing twelve-month figure through Jul 2025 was $15.1 million (up 34.97% YoY), and the FY2025 annual result was $12.3 million, down 43.92% from the prior year.
• Share-based Compensation came in at $5.4 million for Q3 2025 at KalVista Pharmaceuticals, up from $3.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.4 million in Q3 2025 to a low of $1.2 million in Q1 2021.
• The 5-year median for Share-based Compensation is $2.8 million (2021), against an average of $2.9 million.
• Across the five-year window, Share-based Compensation soared 215.69% in 2021 and decreased 22.87% in 2022, its largest moves.
• KalVista Pharmaceuticals' Share-based Compensation stood at $2.9 million in 2021, then slipped by 12.38% to $2.5 million in 2022, then grew by 27.97% to $3.2 million in 2023, then decreased by 6.49% to $3.0 million in 2024, then surged by 79.36% to $5.4 million in 2025.
• The last three Share-based Compensation figures came in at $5.4 million (Q3 2025), $3.6 million (Q2 2025), and $3.0 million (Q4 2024), per Business Quant data.